A Phase 1 Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies
NCT #
NCT04354246
Condition(s)
Ovarian/ Peritoneal/ Fallopian Tube Cancer
Molecular Target(s)
PVRIG, TIGIT
Drug Classification(s)
Monoclonal Antibody
Agents(s)
TIGIT& PVRIG
Phase(s)
I
Mechanism of Action
COM701 is a monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), a regulatory signal molecule expressed on cytotoxic T lymphocytes and NK cells. Blockade of PVRIG can prevent PVRIG-induced inhibition of T-lymphocyte and NK-cell activation. This sequence could enhance anti-tumor responses and immune-mediated tumor cell killing.
Purpose
- How much of study agent 1 can be given alone and in combination with study agent 2 and Pembrolizumab with an acceptable level of side effects
- The effects of the study agents (good and bad)
- How much of the study agents are absorbed into the blood and how fast they are removed
- If research tests can be used in the future to predict who will benefit from the study agent 1 and/or study agent 2
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.